ProCE Banner Activity

Phase II VAYHIT3 Interim Results: Ianalumab in Previously Treated Primary Immune Thrombocytopenia 

Conference Coverage
Slideset

Ianalumab, a novel humanized anti-BAFF monoclonal antibody, showed preliminary evidence of activity with no unexpected toxicity in heavily pretreated patients with primary ITP.

Released: December 11, 2024

Expiration: December 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation